Table 2.
Characteristics of included studies: baseline characteristics systematic reviews of randomized controlled trials.
| Characteristics | Among women with PCOS | Among women with clomiphene resistant PCOS | ||||||
|---|---|---|---|---|---|---|---|---|
| Salehpour et al. 2009 [17] | Gayatri et al. 2010 [28] | Oner and Muderris 2011 [18] | Salehpour et al. 2012 [19] | Rizk et al. 2005 [20] | Elnashar et al. 2007 [14] | Hashim et al. 2010 [21] | Nasr 2010 [22] | |
| NAC/placebo | NAC/metformin | NAC/metformin | NAC/placebo | NAC/placebo | NAC/metformin | NAC/metformin | NAC/placebo | |
| Total randomized, n | 46 | 115 | 100 | 180 | 153 | 64 | 192 | 60 |
| Randomised, n | 46 | 56/59 | 50 /50 | 90/90 | NA | 32/32 | 95/97 | 30/30 |
| Completed, n | 36 | 50/50 | 45/31 | 82/85 | 75/75 | 30/31 | 97/95 | 30/30 |
| Total, n | 36 | 100 | 76 | 167 | 150 | 61 | 192 | 60 |
| Attrition rate | 21.7% | 13% | 24% | 7% | 2% | 4.7% | 0% | 0% |
| Baseline Characteristics | ||||||||
| Age, years | 27.2 (5.4) 27.8 (6.1) |
22.6 (3.8); 23.2 (4.1) |
23.7 (4.4); 22.6 (4.8) |
27.22 (3.32); 27.41 (3.41) |
28.9 (4.7); 28.4 (5.7) |
27.33 (3.35); 26.73 (5.36) |
27.3 (2.6); 26.8 (2.2) |
28.4 (4.2); 29.2 (3.7) |
| Weight, kg | 74.1 (11.7) 74.1 (13.2) |
70.5 (3.45); 69.8 (8.32) |
NA | NA | 101.3 (12.4); 99.2 (12.3) |
NA | NA | NA |
| BMI, kg/m2 | 29.5 (4.1) 29.5 (4.4) |
26.54 (2.35); 27.28 (3.25) |
23 (4.6); 24.3 (6.2) |
26.78 (2.24); 26.67 (2.01) |
30.5 (2.6); 30.1 (3.1) |
25.8 (0.94); 26.8 (1.52) |
26.6 (2.2); 26.3 (2.3) |
28.6 (3.7); 29.1 (4.2) |
| Amenorrhea patients (%) | 2 (11.1%) 2 (11.1%) |
4 (8%); 4 (8%) |
NA | NA | NA | NA | 6 (6.3%); 7 (7.2%) |
5 (17%); 6 (20%) |
| Oligomenorrhea, n (%) | NA | 29 (58%); 30 (60%) |
NA | NA | NA | 76.7 (23); 77.4 (24) |
89 (93.7%); 90 (92.8%) |
NA |
| Hirsutism, n (%) | 11 (61.1%) 10 (55.6%) |
2 (4%); 3 (6%) |
NA | NA | NA | NA | NA | 16 (53%); 18 (60%) |
| Acne, n (%) | 5 (27.8%) 5 (27.8%) |
1 (2); 2 (4) | NA | NA | NA | NA | NA | NA |
| Duration of Infertility, mean (SD) | 4.5 (2.2) 4.2 (3.3) |
10 (20); 8 (16) |
NA | 4.39 (1.96); 4.45 (1.94) |
5 (2.9); 4.4 (2.6) |
NA | 4.5 (1.2); 4.7 (1.3) |
5.3 (1.9); 4.9 (2.1) |
| Testosterone level, nmol/dL, mean (SD) | 0.91 (0.48) 1.01 (0.45) |
1.55 (0.29); 1.65 (0.24) |
80.8 (41.1); 86.1 (48.4) |
NA | NA | 98.27 (31.5); 106.5 (44.6) |
1.06 (0.27); 1.03 (0.31) |
NA |
| FPG, mg/dL, mean (SD) | 95.6 (10.9) 96.8 (27.7) |
88.53 (5.14); 87.65 (4.34) |
88.5 (6.8); 88.9 (7.4) |
NA | 81.9 (12.6); 85.9 (14.1) |
83.3 (8.8); 85.9 (9.4) |
91.3 (1.5); 89.6 (1.4) |
NA |
| HOMA-IR | 5.22 (5.58); 4.9 (4.2) |
5.52 (1.35); 5.42 (1.36) |
4.5 (1.2); 4.3 (0.9) |
NA | NA | NA | NA | NA |